Literature DB >> 26690786

Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D3.

Asiri R Wijenayaka1, Matthew Prideaux2, Dongqing Yang2, Howard A Morris3, David M Findlay2, Paul H Anderson3, Gerald J Atkins2.   

Abstract

The osteocyte expressed gene SOST encodes sclerostin, a potent negative regulator of bone formation and inducer of bone resorption. We have recently demonstrated that the human SOST gene is positively regulated in response to 1α,25-dihydroxyvitamin D3 (1,25D). Responsiveness may be mediated at least in part by a single classical DR3-type vitamin D response element (VDRE). In this study we examined the early responsiveness of the SOST gene to both 1,25D and to parathyroid hormone (PTH), a known repressor of SOST expression, in SaOS2 cells differentiated to an osteocyte-like stage of cell maturation. Both SOST mRNA levels and sclerostin protein levels increased in these cultures as early as 3h post-treatment with 1,25D and declined in response to PTH in the same timeframe. For 1,25D, the level of induced SOST appeared dependent on the extent, to which the degradative enzyme 1,25-dihydroxyvitamin D 24-hydroxylase (CYP24A1) was induced. Together with the observed rapid decrease in SOST/sclerostin levels in response to PTH, endocrine regulation of sclerostin production appears to be an important determinant of sclerostin levels. These findings confirm that the human SOST gene and sclerostin expression can be considered to be directly 1,25D-responsive in osteocytes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,25-Dihydoxyvitamin D; Osteocyte; Sclerostin

Mesh:

Substances:

Year:  2015        PMID: 26690786     DOI: 10.1016/j.jsbmb.2015.12.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification.

Authors:  Loan Nguyen-Yamamoto; Ken-Ichiro Tanaka; Rene St-Arnaud; David Goltzman
Journal:  JCI Insight       Date:  2019-07-11

Review 2.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

3.  Construction of adenovirus vector expressing duck sclerostin and its induction effect on myogenic proliferation and differentiation in vitro.

Authors:  Hehe Liu; Yanying Li; Qian Xu; Jianmei Wang; Chunchun Han; Lili Bai; Liang Li
Journal:  Mol Biol Rep       Date:  2022-02-06       Impact factor: 2.316

Review 4.  Sclerostin: From Molecule to Clinical Biomarker.

Authors:  Ahmed Omran; Diana Atanasova; Filip Landgren; Per Magnusson
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 6.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

Review 7.  The Role of Sclerostin in Bone Diseases.

Authors:  Elias S Vasiliadis; Dimitrios-Stergios Evangelopoulos; Angelos Kaspiris; Ioannis S Benetos; Christos Vlachos; Spyros G Pneumaticos
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.